Hanmi’s Obesity Drug Shows Up to 30% Weight Loss
Hanmi Pharmaceutical’s investigational obesity drug efeglenatide demonstrated weight loss of up to 30%, according to interim results from…
Hanmi Pharmaceutical
6 개의 기사가 있습니다.
Hanmi Pharmaceutical reveals Phase 1 results for triple agonist obesity drug HM15275
Hanmi Pharmaceutical has released the first clinical data from its next-generation triple agonist obesity drug, HM15275, showing promising…
Hanmi and GC Biopharma Begin Fabry Disease Trials in Korea
Hanmi Pharmaceutical and GC Biopharma are set to begin clinical trials in Korea for their Fabry disease treatment,…
12 Healthcare Stocks Including Celltrion Added to K-Value Up Index
The government has selected the ‘Korea Value Up’ Index as part of its efforts to address the Korea…
Hanmi Pharmaceutical Board Rejects Nomination of Lim JongYoon as CEO
Park Jaehyun, CEO of Hanmi Pharmaceutical, retained his position following a board decision that rejected the proposal to…
Hanmi Pharmaceutical's Q2 Operating Profit Up 75% To KRW 58.1 Billion
Hanmi Pharmaceutical has achieved robust performance due to strong sales of key products and the growth of its…